Bluebird bio spikes even as CRISPR leads in gene therapy rollout

seekingalpha05-10

Bluebird bio (NASDAQ:BLUE) shares climbed on Thursday, even as its rival CRISPR Therapeutics (NASDAQ:CRSP) indicated a faster rollout in the race to market two recently approved gene therapies for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2434046536?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1207032003/image_1207032003.jpg","is_english":true,"pubTime":"2024-05-10 02:10","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2434046536","market":"sh","top_or_hot":-1,"title":"Bluebird bio spikes even as CRISPR leads in gene therapy rollout","media":"seekingalpha","content":"<div>\n<p>Bluebird bio (NASDAQ:BLUE) shares climbed on Thursday, even as its rival CRISPR Therapeutics (NASDAQ:CRSP) indicated a faster rollout in the race to market two recently approved gene therapies for ...</p>\n\n<a href=\"https://seekingalpha.com/news/4103984-bluebird-bio-stock-gains-q1-2024-results\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bluebird bio spikes even as CRISPR leads in gene therapy rollout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBluebird bio spikes even as CRISPR leads in gene therapy rollout\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-10 02:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4103984-bluebird-bio-stock-gains-q1-2024-results><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bluebird bio (NASDAQ:BLUE) shares climbed on Thursday, even as its rival CRISPR Therapeutics (NASDAQ:CRSP) indicated a faster rollout in the race to market two recently approved gene therapies for ...</p>\n\n<a href=\"https://seekingalpha.com/news/4103984-bluebird-bio-stock-gains-q1-2024-results\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://seekingalpha.com/news/4103984-bluebird-bio-stock-gains-q1-2024-results","article_id":"2434046536","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1207032003/image_1207032003.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2434046536","pubTimestamp":1715278233,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Bluebird bio  shares climbed on Thursday, even as its rival CRISPR Therapeutics  indicated a faster rollout in the race to market two recently approved gene therapies for genetically-driven blood disorders. With its Q1 results on Thursday, Bluebird bio  reported the completion of the first patient start  for Lyfgenia, a gene therapy the FDA approved in December for  the treatment of sickle cell disease . Meanwhile, CRISPR Therapeutics , whose gene editing therapy Casgevy developed with Vertex Pharmaceuticals  was approved by the FDA for SCD and beta-thalassemia, said that 'multiple' patients have already had their cells collected to receive its one-time therapy.  Even as Lyfgenia lagged Casgevy in the market rollout, investors sent Bluebird bio  shares higher as the U.S. biotech reported better-than-expected financials for Q1 2024 while its Swiss rival fell short of consensus.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4567":"ESG概念","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4139":"生物科技","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4533":"AQR资本管理(全球第二大对冲基金)","SQQQ":"纳指三倍做空ETF","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","VRTX":"福泰制药","LU0079474960.USD":"联博美国增长基金A","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4578":"CAR-T","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","QID":"纳指两倍做空ETF","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4588":"碎股","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","SCD":"LMP Capital & Income Fund","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","CRSP":"CRISPR Therapeutics AG","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","PSQ":"纳指反向ETF","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","QLD":"纳指两倍做多ETF",".IXIC":"NASDAQ Composite","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","QQQ":"纳指100ETF","LU1861558580.USD":"日兴方舟颠覆性创新基金B","TQQQ":"纳指三倍做多ETF","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BLUE":"bluebird bio Inc.","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4532":"文艺复兴科技持仓"},"translate_title":"即使CRISPR在基因治疗方面领先，蓝鸟生物也达到峰值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1,"SCD":1,"BLUE":1,"CRSP":1,".IXIC":0.9,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"TQQQ":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Bluebird bio (NASDAQ:BLUE) shares climbed on Thursday, even as its rival CRISPR Therapeutics (NASDAQ:CRSP) indicated a faster rollout in the race to market two recently approved gene therapies for genetically-driven blood disorders. With its Q1 results on Thursday, Bluebird bio (BLUE) reported the completion of the first patient start (cell collection) for Lyfgenia, a gene therapy the FDA approved in December for  the treatment of sickle cell disease ((SCD)). Meanwhile, CRISPR Therapeutics (CRSP), whose gene editing therapy Casgevy developed with Vertex Pharmaceuticals (NASDAQ:VRTX) was approved by the FDA for SCD and beta-thalassemia, said that 'multiple' patients have already had their cells collected to receive its one-time therapy.  Even as Lyfgenia lagged Casgevy in the market rollout, investors sent Bluebird bio (BLUE) shares higher as the U.S. biotech reported better-than-expected financials for Q1 2024 while its Swiss rival fell short of consensus.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2434046536"}